In yesterday’s Wall Street session, Seres Therapeutics Inc (NASDAQ:MCRB) shares traded at $0.81, up 18.23% from the previous session.
MCRB stock price is now -1.90% away from the 50-day moving average and -9.84% away from the 200-day moving average. The market capitalization of the company currently stands at $138.97M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
, while ‘JP Morgan’ rates the stock as ‘Neutral’
In other news, DesRosier Thomas, Chief Legal Officer and EVP sold 878 shares of the company’s stock on Nov 18 ’24. The stock was sold for $475 at an average price of $0.54. Upon completion of the transaction, the Chief Legal Officer and EVP now directly owns 135,192 shares in the company, valued at $0.11 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 18 ’24, von Moltke Lisa sold 977 shares of the business’s stock. A total of $528 was realized by selling the stock at an average price of $0.54. This leaves the insider owning 32,415 shares of the company worth $26256.15. A total of 26.98% of the company’s stock is owned by insiders.
During the past 12 months, Seres Therapeutics Inc has had a low of $0.54 and a high of $2.05. As of last week, the company has a debt-to-equity ratio of 3.91, a current ratio of 1.12, and a quick ratio of 1.12. The fifty day moving average price for MCRB is $0.83436 and a two-hundred day moving average price translates $0.9042 for the stock.
The latest earnings results from Seres Therapeutics Inc (NASDAQ: MCRB) was released for 2024-09-30. The net profit margin was -269034.37% and return on equity was -3758.21% for MCRB.
